Positron Corp (POSC) as of December 31, 2025 presents a marginally positive but structurally fragile liquidation posture at the equity level, driven almost entirely by a $2.5M cash balance against a relatively thin liability stack. MFFAIS reports a cash liquidation value of $2.33M and an operating liquidation value of $3.02M, consistent with the balance sheet math below. Total assets of $4.0M are dominated by cash ($2.5M, 100% recoverable), inventory ($680K net of write-down, 60% haircut yields ~$408K), prepaid/other current (~$130K, negligible recovery), deposits ($375K noncurrent, uncertain recovery), PP&E net ($106K, 50-70% yields ~$53-74K), and ROU asset ($180K, zero recovery in liquidation). Against total liabilities of $2.56M at face value — comprising current accounts payable/accrued ($407K), deferred revenue ($120K obligation), customer deposits ($50K), accrued liabilities ($700K, likely includes accrued interest and other items), a related-party note payable current ($1.2M Note #1 extended to June 2026, secured by the sole PET-CT imaging device in inventory), operating lease liability ($184K present value, persists in windup), and a $563K convertible note payable — the arithmetic yields rough equity recovery in the range of $0 to $0.5M depending on deposit recoverability and haircut assumptions, with the lease liability and face-value liabilities consuming most of the haircut-adjusted asset pool. The $700K AccruedLiabilitiesAndOtherLiabilities tag is separately reported but its composition is not fully disaggregated in XBRL; it may overlap with or supplement the $81K AccountsPayableAndAccruedLiabilitiesCurrent. The company completed a major capital restructuring in 2025: raised $10M in equity from a related party (8M shares at $1/share to a principal stockholder), repurchased and retired 4M shares for $2.5M, converted all preferred stock to common, recognized $5.0M in fully-vested stock option expense (non-cash, no asset value), and wrote down $577K of inventory. The remaining Note #1 balance of $1.2M is collateralized by the sole imaging device in inventory (which was carried at $1.26M gross before write-down); the lender has authorized sale of collateral. A subsequent event discloses $325K was repaid on Note #1 after year-end from working capital, reducing that obligation to approximately $875K. The new operating lease (July 2025, 5-year, $184K PV) is a full-face liability in liquidation. The filing discusses a strategic cooperation agreement with a supplier contingent on FDA clearance of a next-generation PET/CT 4D system; no purchase obligations are quantified in XBRL as the arrangement is conditional and not unconditional per ASC 440. Federal NOL carryforwards of ~$50M (with ~$44M beginning to expire in 2026) carry zero liquidation value given the full valuation allowance.
▼ Community Notes